Hernandezine promotes cancer cell apoptosis and disrupts the lysosomal acidic environment and cathepsin D maturation

Abstract

Hernandezine (Her), a bisbenzylisoquinoline alkaloid extracted from Thalictrum flavum, is recognized for its range of biological activities inherent to this herbal medicine. Despite its notable properties,the anti-cancer effects of Her have remained largely unexplored. In this study, we elucidated that Her significantly induced cytotoxicity in cancer cells through the activation of apoptosis and necroptosis mechanisms. Furthermore, Her triggered autophagosome formation by activating the AMPK and ATG5 conjugation systems, leading to LC3 lipidation. Our findings revealed that Her caused damage to the mitochondrial membrane, with the damaged mitochondria undergoing mitophagy, as evidenced by the elevated expression of mitophagy markers. Conversely, Her disrupted autophagic flux, demonstrated by the upregulation of p62 and accumulation of autolysosomes, as observed in the RFP-GFP-LC3 reporter assay. Initially, we determined that Her did not prevent the fusion of autophagosomes and lysosomes. However, it inhibited the maturation of cathepsin D and increased lysosomal pH, indicating an impairment of lysosomal function. The use of the early-stage autophagy inhibitor, 3-methyladenine (3-MA), did not suppress LC3II, suggesting that Her also induces noncanonical autophagy in autophagosome formation. The application of Bafilomycin A1, an inhibitor of noncanonical autophagy, diminished the recruitment of ATG16L1 and the accumulation of LC3II by Her, thereby augmenting Her-induced cell death. These observations imply that while autophagy initially plays a protective role, the disruption of the autophagic process by Her promotes programmed cell death. This study provides the first evidence of Her’s dual role in inducing apoptosis and necroptosis while also initiating and subsequently impairing autophagy to promote apoptotic cell death. These insights contribute to a deeper understanding of the mechanisms underlying programmed cell death, offering potential avenues for enhancing cancer prevention and therapeutic strategies.

Keywords

Hernandezine / Apoptosis / Mitophagy / Autophagic flux / Lysosome / Noncanonical autophagy

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.

[2] Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview[J]. Cancers, 2014, 6(3): 1769-1792.

[3] Li M, Wu C, Muhammad JS, et al. Melatonin sensitises shikonin-induced cancer cell death mediated by oxidative stress via inhibition of the SIRT3/SOD2-AKT pathway[J]. Redox Biol, 2020, 2020(36): 101632.

[4] Zakki SA, Muhammad JS, Li JL, et al. Melatonin triggers the anticancer potential of phenylarsine oxide via induction of apoptosis through ROS generation and JNK activation[J]. Metallomics, 2020, 12(3): 396-407.

[5] Fuchs Y, Steller H. Live to die another way: modes of programmed cell death and the signals emanating from dying cells[J]. Nat Rev Mol Cell Biol, 2015, 16(6): 329-344.

[6] Wong SQ, Kumar A V, Mills J, et al. Autophagy in aging and longevity[J]. Hum Genet, 2020, 139(3): 277-290.

[7] Chi KH, Wang YS, Huang YC, et al. Simultaneous activation and inhibition of autophagy sensitizes cancer cells to chemotherapy[J]. Oncotarget, 2016, 7(36): 58075-58088.

[8] Lemasters JJ. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging[J]. Rejuvenation Res, 2005, 8(1): 3-5.

[9] Fodale V, Pierobon M, Liotta L, et al. Mechanism of cell adaptation[J]. Cancer J, 2011, 17(2): 89-95.

[10] Kuok C, Wang Q, Fong P, et al. Inhibitory effect of Hernandezine on the proliferation of hepatocellular carcinoma[J]. Biol Pharm Bull, 2023, 46(2): 245-256.

[11] Song C, Hu Y, Mang Z, et al. Hernandezine induces autophagic cell death in human pancreatic cancer cells via activation of the ROS/AMPK signaling pathway[J]. Acta Pharmacol Sin, 2023, 44(4): 865-876.

[12] Wang X, Li X, Xia Y, et al. Hernandezine regulates proliferation and autophagy-induced apoptosis in melanoma cells[J]. J Nat Prod, 2022, 85(5): 1351-1362.

[13] Law BYK, Mok SWF, Chan WK, et al. Hernandezine, a novel AMPK activator induces autophagic cell death in drug-resistant cancers[J]. Oncotarget, 2016, 7(7): 8090-8104.

[14] Law BYK, Michelangeli F, Qu YQ, et al. Neferine induces autophagy-dependent cell death in apoptosis-resistant cancers via ryanodine receptor and Ca²⁺-dependent mechanism[J]. Sci Rep, 2019, 9(1): 20034.

[15] Wu JM, Chen Y, Chen JC, et al. Tetrandrine induces apoptosis and growth suppression of colon cancer cells in mice[J]. Cancer Lett, 2010, 287(2): 187-195.

[16] Zhao Y, Lv JJ, Chen J, et al. Berbamine inhibited the growth of prostate cancer cells in vivo and in vitro via triggering intrinsic pathway of apoptosis[J]. Prostate Cancer Prostatic Dis, 2016, 19(4): 358-366.

[17] Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry[J]. Nat Protoc, 2006, 1(3): 1458-1461.

[18] Yuan J, Dong X, Yap J, et al. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy[J]. J Hematol Oncol, 2020, 13(1): 113.

[19] Vara-Perez M, Felipe-Abrio B, Agostinis P. Mitophagy in cancer: a tale of adaptation[J]. Cells, 2019, 8(5): 493.

[20] Gao Y, Liu Y, Hong L, et al. Golgi-associated LC3 lipidation requires V-ATPase in noncanonical autophagy[J]. Cell Death Dis, 2016, 7(8): e2330.

[21] Jacquin E, Leclerc-Mercier S, Judon C, et al. Pharmacological modulators of autophagy activate a parallel noncanonical pathway driving unconventional LC3 lipidation[J]. Autophagy, 2017, 13(5): 854-867.

[22] Safarzadeh E, Sandoghchian SS, Baradaran B. Herbal medicine as inducers of apoptosis in cancer treatment[J]. Adv Pharm Bull, 2014, 4(Suppl 1): 421-427.

[23] Tavakoli J, Miar S, Majid ZM, et al. Evaluation of effectiveness of herbal medication in cancer care: a review study[J]. Iran J Cancer Prev, 2012, 5(3): 144-156.

[24] Galluzzi L, Green DR. Autophagy-independent functions of the autophagy machinery[J]. Cell, 2019, 177(7): 1682-1699.

[25] Galluzzi L, Bravo-San Pedro JM, Levine B, et al. Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles[J]. Nat Rev Drug Discov, 2017, 16(7): 487-511.

[26] Fujita N, Itoh T, Omori H, et al. The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy[J]. Mol Biol Cell, 2008, 19(5): 2092-2100.

[27] Li YJ, Lei YH, Yao N, et al. Autophagy and multidrug resistance in cancer[J]. Chin J Cancer, 2017, 36(1): 52.

[28] Fu R, Deng Q, Zhang H, et al. A novel autophagy inhibitor berbamine blocks SNARE-mediated autophagosome-lysosome fusion through upregulation of BNIP3[J]. Cell Death Dis, 2018, 9(2): 243.

[29] Porter K, Nallathambi J, Lin Y, Liton PB (2013) Lysosomal basification and decreased autophagic flux in oxidatively stressed trabecular meshwork cells. Autophagy 9: 581-594. https://doi.org/10.4161/auto.23568.

[30] Mancias JD, Kimmelman AC. Mechanisms of selective autophagy in normal physiology and cancer[J]. J Mol Biol, 2016, 428: 1659-1680.

[31] Lazarou M, Sliter DA, Kane LA, et al. The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy[J]. Nature, 2015, 524: 309-314.

[32] Kucharewicz K, Dudkowska M, Zawadzka A, et al. Simultaneous induction and blockade of autophagy by a single agent[J]. Cell Death Dis, 2018, 9: 353.

[33] Feng X, Zhou J, Li J, et al. Tubeimoside I induces accumulation of impaired autophagolysosome against cervical cancer cells by both initiating autophagy and inhibiting lysosomal function[J]. Cell Death Dis, 2018, 9: 1117.

[34] Ranieri R, Ciaglia E, Amodio G, et al. N6-isopentenyladenosine dual targeting of AMPK and Rab7 prenylation inhibits melanoma growth through the impairment of autophagic flux[J]. Cell Death Differ, 2018, 25: 353-367.

[35] Li M, Yang Z, Vollmer LL, et al. AMDE-1 Is a dual function chemical for autophagy activation and inhibition[J]. PLOS ONE, 2015, 10: e0122083.

[36] Zhu F, Zhang W, Yang T, et al. Complex roles of necroptosis in cancer[J]. J Zhejiang Univ-Sc B, 2019, 20: 399-413.

Funding

JSPS KAKENHI(20K10449)

JSPS KAKENHI(23K09645)